+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 12Years - 55Years
All Genders
ID07133997

Study Evaluating Recombinant Erwinia Asparaginase and Venetoclax Combined With Blinatumomab for Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia in Adults

Led by City of Hope Medical Center · Updated on 2026-10-16

26

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a combination of drugsrecombinant Erwinia asparaginase, venetoclax, and blinatumomabin patients aged 12 to 55 who have CD19 positive B-cell acute lymphoblastic leukemia that has returned after treatment or did not respond to previous therapies. This phase 1Ib trial aims to assess the safety, side effects, and how well this combination works to treat this condition. The study is sponsored by City of Hope Medical Center and focuses on understanding toxicities and treatment effectiveness. Participants may receive optional pre-phase therapy with cyclophosphamide, vincristine, and prednisone before starting treatment. The main treatment includes intramuscular injections of recombinant Erwinia asparaginase on specific days, oral venetoclax daily or every other day depending on the cycle, and continuous intravenous blinatumomab during cycles lasting 42 to 49 days. Treatment is repeated for up to two cycles if the disease does not progress or side effects are manageable. During the study, participants undergo heart tests echocardiography and multigated acquisition scan, bone marrow biopsies and aspirations, blood sample collections, and lumbar punctures. Researchers monitor safety by tracking adverse events and toxicities, evaluate treatment response through remission rates and disease markers, and assess minimal residual disease after each cycle. Follow-up occurs 30 days after treatment completion to assess outcomes and safety.

CONDITIONS

Brief Title

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here